| dbo:abstract
|
- ميخائيل ر. هايدن هو عالم أعصاب وعالم وراثة كندي، ولد في 1951 في كيب تاون في جنوب أفريقيا. (ar)
- Michael Reuben Hayden (* 1951 in Kapstadt) ist ein kanadischer Mediziner und Genetiker, der für die Erforschung der Erbkrankheit Chorea Huntington und ihrer Genetik bekannt ist sowie für andere Erbkrankheiten, besonders von Gendefekten bei Störungen des Fettstoffwechsels. (de)
- Michael R. Hayden, CM OBC FRSC (born 1951) is a Killam Professor of Medical Genetics at the University of British Columbia, the highest honour UBC can confer on any faculty member. Only 4 such awards have ever been conferred in the Faculty of Medicine. Dr. Hayden is also Canada Research Chair in Human Genetics and Molecular Medicine. Hayden is best known for his research in Huntington disease (HD). He is a senior scientist and former director of the Centre for Molecular Medicine and Therapeutics (CMMT) in Vancouver, British Columbia, Canada; a genetic research centre within UBC's Faculty of Medicine and affiliated with the BC Children's Hospital Research Institute and the BC Children's Hospital Foundation, which he founded. He was also the Program Director of the Translational Laboratory in Genetic Medicine in Singapore from 2011-2020, and was appointed as the President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries from 2012–2017. During this time, approximately 35 new products were approved in major markets with many for diseases of the CNS and led the approval of Austedo for chorea in HD, the second drug ever to be approved for HD. In 2015, Teva R&D was recognized as one of the 10 most exciting innovators in Pharma by IDEA Pharma and in 2017, Teva R&D ranked top of the industry for CNS development and clinical trial success by Pharma Intelligence. Hayden is the most cited author in the world for Huntington disease and ABCA1, and has authored over 900 publications and invited submissions (Google Scholar citations 99,672, h-index 160, i10-index 766; Web of Science citations 65,327, h-index 123). In 2007, he received the Prix Galien which recognizes the outstanding contribution of a researcher to Canadian pharmaceutical research; in 2008, recognition from the Canadian Institutes of Health Research (CIHR) as Canada's Health Researcher of the Year: CIHR Michael Smith Prizes in Health Research. In 2010, he was awarded Member of the Order of Canada, following his receipt of the Order of British Columbia in 2009. Hayden received the Canada Gairdner Foundation Wightman Award in 2011, recognizing him as a physician-scientist who has demonstrated outstanding leadership in medicine and medical science. He was inducted into the Canadian Medical Hall of Fame in 2017. Most recently in 2020, Hayden was awarded the David Dubinsky Humanitarian Award from the American Friends of Soroka Medical Center (AFSMC). In addition to his academic work, Hayden is the co-founder of five biotechnology companies including: Prilenia, NeuroVir Therapeutics Inc., Xenon Pharmaceuticals Inc., Aspreva Pharmaceuticals Corp and 89Bio and the CEO of Prilenia Therapeutics. He currently sits on different public and private boards of biotechnologies companies. (en)
|
